Lanean...
Moving into the mainstream: healthcare professionals’ views of implementing treatment focussed genetic testing in breast cancer care
A proportion of breast cancers are attributable to BRCA1 or BRCA2 mutations. Technological advances has meant that mutation testing in newly diagnosed cancer patients can be used to inform treatment plans. Although oncologists increasingly deliver treatment-focused genetic testing (TFGT) as part of...
Gorde:
| Argitaratua izan da: | Fam Cancer |
|---|---|
| Egile Nagusiak: | , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Springer Netherlands
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6560008/ https://ncbi.nlm.nih.gov/pubmed/30689103 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10689-019-00122-y |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|